Cargando…
AB004. Radiotherapy for thymic epithelial tumors: what is the optimal dose?—a systematic review
BACKGROUND: Thymic epithelial tumors (TETs) are rare thoracic tumors, often requiring multimodal approaches. Surgery represents the first step of the treatment, possibly followed by adjuvant radiotherapy (RT) and, less frequently, chemotherapy. For unresectable tumors, a combination of chemotherapy...
Autores principales: | Angrisani, Antonio, Houben, Ruud, Marcuse, Florit, Hochstenbag, Monique, Maessen, Jos, De Ruysscher, Dirk, Peeters, Stephanie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792816/ http://dx.doi.org/10.21037/med-22-ab004 |
Ejemplares similares
-
AB003. Benefits of proton radiotherapy in thymic epithelial tumors using the model-based approach
por: Peeters, Stephanie T. H., et al.
Publicado: (2022) -
“Radiotherapy for thymic epithelial tumors: What is the optimal dose? A systematic review.”
por: Angrisani, A., et al.
Publicado: (2022) -
The association between anti‐acetylcholine receptor antibody level and clinical improvement in myasthenia gravis
por: Marcuse, Florit, et al.
Publicado: (2022) -
Expression of pRb and p16INK4 in human thymic epithelial tumors in relation to the presence of human polyomavirus 7
por: Keijzers, Marlies, et al.
Publicado: (2015) -
A Phase I Study of Concurrent Individualized, Isotoxic Accelerated Radiotherapy and Cisplatin–Vinorelbine–Cetuximab in Patients With Stage III Non–Small-Cell Lung Cancer
por: Dingemans, Anne-Marie C., et al.
Publicado: (2014)